New Zealand raises concerns with Upjohn/Mylan tie-up

The proposed merger of Pfizer’s off-patent branded and generic established medicines business with Mylan raises competition concerns over the supply of several molecules, New Zealand’s competition watchdog has said.


Get unlimited access to all Global Competition Review content